Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
Completed
AbbVie
Phase 2
2008-11-26
This study is designed to evaluate the safety and beneficial effects of elagolix (NBI-56418)
compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month
period followed by an additional three months of treatment on elagolix.
Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
Completed
AbbVie (prior sponsor, Abbott)
Phase 2
2008-11-26
This study is designed to evaluate the safety and beneficial effects of elagolix (NBI-56418)
compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month
period followed by an additional three months of treatment on elagolix.
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Completed
AbbVie
Phase 3
2013-09-09
A randomized study evaluating the safety and efficacy of elagolix in the management of
moderate to severe endometriosis-associated pain in adult premenopausal female subjects.
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Completed
AbbVie
Phase 3
2015-12-22
This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in
combination with estradiol/norethindrone acetate for the management of heavy menstrual
bleeding associated with uterine fibroids in premenopausal women.
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
Completed
AbbVie
Phase 3
2016-02-03
This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in
combination with estradiol/norethindrone acetate for the management of heavy menstrual
bleeding associated with uterine fibroids in premenopausal women.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
